CFZ533 (iscalimab)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for CFZ533 (iscalimab), covering 2026-03-23 to 2026-03-23. Get the full timeline:
Most recent: Clinical Trial Update: Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients [Phase 2]